624 530, 531 refractory anemia with prothrombin time 458 pseudo-Gaucher cells 634 pseudo-Pelger neutrophil excess blasts 230, 231, 624 \200\2235 refractory anemia 236 with excess blasts in transformation 230, 624 \200\2235 pseudopolycythaemia 10 pseudothrombocytopenia 462, 464 refractory anemia with pseudotumours 476 pseudo-vWD 485 psoriatic arthropathy 38 psychological support 673 pulmona ry embolism 518, 264 \200\2235, 278 senile purpura 20 septic shock (sepsis) 636 \200\2237, 684, 686 \200\223 7 serum ferritin 9, 43, 107 serum paraprotein 25 severe combined ringed sideroblasts 230, 231, 242, 243 refractory cytopenia with multilineage dysplasia (wi th ringed sideroblasts) 231 refractory cytopenia with unilineage dysplasia 230, 231 521 \200\2232 pure red cell aplasia 106 purine analogs, prophylaxis 688 purine nucleoside phosphorylase d efi ciency 546 immunodefi ciency (SCID) 546 \200\2237 sex hormones 36 S zary syndrome 167, 199, relative erythrocytosis 264, 265, 279 201, 205 \200\2236 sharps injury 708 Shwachman \200\223Diamond syndrome 597 \200\2238 sickl e/ thalassaemia renal cell cancer 393 renal disease 34 \200\2235, 498 reptilase time 459 respiratory syncyt ial virus purpura 18, 20 post-transfusion 492, 643 Purtilo syndrome 632 pyknocytosis, infantile 577 pyridoxine defi ciency 51 pyrimidine 5 \200\231 nucleotidase 687 65, 81 sickle/C 81 sickle cell anemia 56 \200\22360, reticular dysgenesis 546 reticulocyte Hb defi ciency 92 \200\2233 concentration 43 reticulocytes 33, 561, 749 retinoblastoma 608 retroperitoneal fi brosis 79 2 reverse transcriptase inhibitors 556 Revised International pyruvate kinase defi ciency 81 91 sickle cell disease 30, 395 sickle cells 33, 59 sickle cell trait 30, 64, 81 sickle crises 666, 672 sickle/D 81 sickle test 30 sickling disorders 56 \200\22365 Q quality of life 668 Prognostic Index 187 823 INDEX systemic mastocytosis with an associated hematological non- mast cell disease 312, 319 factors infl uencing outcome 390 fertility issues 450 foreign travel 449 fungal infections 442 \200\2234 graft-versus-host disease sinusoidal obstruction syndrome 438 \200\22340 slapped cheek 632 small cell lung cancer 393 small lymphocytic lymphoma systemic sclerosis 394 190, 192, 194 \200\2236 391, 428 \200\22336 smoking 10 smoldering chronic graft-versus-host disease prophylaxis 424 \200\2237 graft-versus-leukemia T tacrolimus 427 tapeworms 633 target cells 33 TAR syndrome 486, 596 TB 687 T-cell acute ly mphoblastic leukemia 144, 755 lymphocytic leukemia 162 eff ect 388 HLA hierarchy 398 indications 392 \200\2236 investigations 404 \200\2235 JACIE accreditation 388 longer term eff ects 450 non-cryopreserved stem cell infusion 418 periphe ral blood stem cell mobilization and harvesting 388, 410 \200\22311 post-transplant smoldering myeloma 25, 332 \200\2234 smoldering systemic mastocytosis 319 sodium chlorate 634 soft cell sarcoma 393 soft tissue sarcoma 396 Sokol Score 151, 808 solitary extraosseous T-cell large granular lymphocyte leukemia 167, 174 \200\2235 plasmacytoma 366 \200\2237 solitary mastocytoma 313 solitary plasmacytoma of T-cell prolymphocytic leukemia 167 T-cell rich B-cell lymphoma bone 366 198 T cells 118 teardrop red blood cells 33 TET2 261 thalassaemias 70 \200\2239 vaccination 448 \200\2239 soluble transferrin assay 43 Southeast Asian pretransplant investigation of donors 406 reduced intensity ovalocytosis 87 spherocytes 33 spherocytic hereditary elliptocytosis 87 thalassaemia 72 \200\2233, 81 thalassaemia 74 \200\2238, conditioning 389, 415 relapse, post-allogeneic spherocytosis, hereditary 79, 81 transplant 451 RhD mismatch 422 sinusoidal obstruction syndrome 438 \200\22340 umbilical co rd blood 400 veno-occlusive disease 84 \200\2236 thalassaemia 79 thalassaemias 79 stem cell transplant 395, spinal collapse 662 splenic marginal zone lymphoma 166, 190 \200\2231, 192, 197 splenomegaly 5 spur cell anemia 41 spurious polycytha emia 10 SQUID 108 Stanford V 743 \200\2234 starvation 51 stem cell leukemia- lymphoma 308 414 thrombin generation 456, 457 438 \200\22340 thrombin time 459 thrombocythaemia, essential 281 \200\2238 thrombocytopenia 18 storage disorders 395, 634 storage pool disorders 464, 486 stress polycythaemia 10 subacute necrotizing lymphadenitis 789 acquired 490 \200\2231 congenital 485 congenital sucrose lysis 751 supportive care 667 \200\22373 surgery stem cell transplantation amegakaryocytic 596 diff erential diagnosis 19 drug-induced 468, 492 \200\2233 heparin-indu ced 512, 542 \200\2233, 654 \200\2235, 704 387 \200\223452 ABO mismatch 421, 422 allogeneic 389, 398 \200\223400, bleeding 28 \200\2239, 467, 506 \200\2237 intra-operative cell salvage 777 448 autologous 389, 402, 449 blood product support hypersplenism 492 liver disease 496 neonatal alloimmune 485, Jehovah \200\231s Witnesses 780 \200\2231 420 \200\2232 maximum surgical blood ordering schedule 778 bone marrow harvesting 586 \200\2237 388, 408 \200\2239 pregnancy 27, 492 TAR syndrome 486, 596 oral anticoagulation 515 pre-operative CMV 446 \200\2237 complications 390 \200\2231 conditioning 389, 399, thrombocytosis 16 \200\22317 thromboelastography 459 thrombolytic therapy overdosage 651 th rombophilia 454 haemodilution 777 thromboprophylaxis 414 \200\22315 525 \200\2236 cryopreserved stem cells symptoms, presenting 2 \200\2233 systemic lupus 412, 416 \200\22317 discharge and follow-up acquired 454, 534 \200\2237 heritable 530 \200\2232 thromboplastin 458 thromboprophylaxis 5 24 \200\2236 erythematosus 632 systemic mastocytosis 312, 391, 452 donor lymphocyte infusion 451 316 \200\22322 824 INDEX U umbilical cord transplants Waldeyer \200\231s ring 185 warfarin 514 \200\22315, 536, 706 thrombosis 22, 518 \200\22322 essential overdosage 656 thrombocythaemia 288 400 warm antibody induced haemolysis 98 \200\2239 \200\230washed \200\231 platelets 769 websit es 796 \200\223801 Well \200\231s score 519 white blood cell count unfractionated heparin 510, risk assessment 524 \200\2236, 704 \200\2235 528, 529 uraemic bleeding 498 urine thrombotic thrombocytopenic purpura 538 \200\2239, 664 \200\2235 alkalinization 691 haemosiderin 750 paraprotein 25 children 560 elevated 12 \200\22313 reduced 14 \200\22315 thyroid disorders 36 thyrotoxicosis 36 tissue factor 456 TORCH infections 632 tramadol 671 tranexamic acid 470, 659, urticaria pigmentosa 632 WHO-based Prognostic Scoring System (WPSS) 240 V variant CJD 479, 747 vegans 8, 46, 633 vena cava fi lters 522 veno-occlusive disease WHO classifi cation 777 lymphoid neoplasms 182, transcobalamin II defi ciency 183 \200\2234 50 mastocytosis 312 myelodysplastic % transferrin saturation 108 438 \200\22340 syndromes 230, 231 transfusion-associated venous thromboembolism myeloproliferative neoplasms 258 circulatory overload 639 518 \200\22322, 536 transfusion-associated graft-versus-host disease 775 risk assessment 524 \200\2236, WHO/ECOG 528, 529 performance status 804 verocytotoxin 540, 606 viral hepatitis 41 vitamin A defi ciency 51 vitamin B6 defi ciency 5 1 vitamin B12 defi ciency 46 \200\2237 vitamin C defi ciency 51 vitamin E defi ciency 51 vi tamin K WHO hematological toxicity scale 805 transfusion haemosiderosis 77, 110 \200\22311 Wilms tumor 396 Wilson disease 83, 632 Wiskott \200\223Aldrich syndrome transfusion reactions 638 \200\22340, 641, 642 transfusion-related acute 547 lung injury 638 transfusion transmitted infections 774 \200\2235 transient abnormal myelopo iesis 625 neonatal defi ciency 488, X X-linked 584 warfarin therapy 656 vitamin K antagonists 514 \200\22315, 706 transient agammaglobulinaemia 548 erythroblastopenia of childhood 592 \200\2233 von Willebrand disease X-linked dyskeratosis congenita 547 transplantation, 472 \200\2235 lymphoproliferative disease following 200 \200\2231; see also stem cell transplantation acquired 284, 499, 500 X-linked voriconazole 443, 444 lymphoproliferative disorder 632 X-linked SCID 547 W Waldenstr m triosephosphate isomerase defi ciency 92 tuberculosis 687 tumor lysis syndrome Z Zieve \200\231s syndrome 41, 82 zinc protoporphyrin 43 macroglobulinaemia 191, 368 \200\22376, 502, 646 \200\2237 690 \200\2231 Fig 2.1 Blood fi lm: chronic renal failure with burr (irregular shaped) cells (E see Fig. 2 .1 p.35). Fig 2. 3 Blood fi lm: normal neutrophil: usually has <5 lobes. This one has 3 lobes (E see Fig. 2.3 p.49). Fig. 2.4 Hypersegmented neutrophils with 7 \200\2238 lobes: found in B12 or folate defi - c iency. Note: blood fi lms and marrow appearances are identical in B12 and folate defi cienc ies (E see Fig. 2.4 p.49). Fig. 2.11 Blood fi lm in hereditary spherocytosis. Note: large numbers of dark spherical re d cells (E see Fig. 2.11 p.86). Fig. 4.1 Bone marrow showing myeloblasts in AML (E see Fig. 4.1 p.125). Fig. 4.2 Bone marrow showing myeloblasts in AML (E see Fig. 4.2 p. 125). Fig. 4.3 AML: myeloblast with large Auer rod (left) (E see Fig. 4.3 p.125). Fig. 4.4 AML: myeloblast with large Auer rod (top of cell) (E see Fig. 4.4 p.126). Fig. 4.5 AML: Sudan Black stain (dark granules clearly seen in myeloblasts) (E see Fig. 4.5 p.126). Fig. 4.6 Gum hypertrophy in patient with AML (E see Fig. 4.6 p.131). Fig. 4.8 Bone marrow: lymphoblasts in ALL L1 (E see Fig. 4.8 p.141). Fig. 4.9 Bone marrow: T-cell ALL showing numerous lymphoblasts (E see Fig. 4.9 p.142). Fig. 4.10 Peripheral blood fi lm in CML: note large numbers of granulocytic cells at all st ages of diff erentiation (low power) (E see Fig. 4.10 p.149). Fig. 4.11 Peripheral blood fi lm in CML: high power (E see Fig. 4.11 p.150). Fig. 4.12 Blood fi lm in CLL showing smear cells (bottom of fi eld) (E see Fig. 4.12 p.159) . Fig. 4.15 Blood fi lm in PLL: cells are larger than those seen in CLL have large prominent nucleoli and moderate chromatin condensation (E see Fig. 4.15 p.169). Fig. 4.16 Blood fi lm in HCL showing typical \200\230hairy \200\231 lymphocytes (medium po wer) (E see Fig. 4.16 p.171). Fig. 4.17 Blood fi lm in HCL showing typical \200\230hairy \200\231 lymphocytes (high powe r) (E see Fig. 4.17 p.171). Fig. 4.19(a) Blood fi lms showing typical ATL cell with lobulated \200\230clover leaf \200\231 nucleus \200\231 (E see Fig. 4.19(a) p.179). Fig. 4.19(b) Blood fi lms showing typical ATL cell with lobulated \200\230clover leaf \200\231 nucleus \200\231 (E see Fig. 4.19(b) p.179). Fig. 5.1 Blood fi lm in S zary syndrome showing typical cerebriform nuclei (E see Fig. 5.1 (a) p.200). Fig. 5.2 PET and CT scans in patient with nodular sclerosing Hodgkin lymphoma demonstrating active disease (moderate FDG uptake on PET) in residual anterior mediastinal mass on CT af ter ABVD chemotherapy (E see Fig. 5.2 p.218). Fig. 6.1 Blood fi lm in MDS showing bilobed pseudo-Pelger neutrophil (E see Fig. 6.1 p.236) . Fig. 6.2 Bone marrow in RARS stained for iron: note iron granules round the nucleus of the erythroblast (E see Fig. 6.2 p.243). Fig. 7.1 Bone marrow trephine in myelofi brosis: note streaming eff ect caused by intense f i brosis (E see Fig. 7.1 p.294). Fig. 8.1 Electrophoresis: from L l R: urine with BJP and generalized proteinuria (albumin b and at top of strip, BJP near foot); serum M band in myeloma; poly- clonal gammopathy; norm al sample, showing albumin, , E, and globulins (E see Fig. 8.1 p.338). Fig. 8.2 Bone marrow aspirate in myeloma showing numerous plasma cells (E see Fig. 8.2 p.34 1). Plate 1 Radiograph of pelvis in a patient with multiple myeloma showing abnormal low densit y bone texture in the left superior pubic ramus and ischium (E see p.338). Plate 2 MRI of cervical and thoracic spine in a patient with multiple myeloma: substantial extra-osseous mass at T1 displacing the spinal cord anteriorly and causing some cord compre ssion (E see Investigations and diagnosis p.338). Plate 3 MRI of pelvis in a patient with multiple myeloma (same as Plate 29 ) showing corres ponding soft tissue mass replacing bone & numerous widespread foci of signal change through out the bony pelvis representing myeloma deposits (E see p.338). Plate 4 T1 sagittal sequence MRI of thoraco-lumbar spine in a patient with multiple myeloma showing multiple myeloma deposits and partial collapse of one vertebral body (E see p.338) .